EyePoint Pharmaceuticals(DE:PV3B)
€0.28-0.01 (-2.80%)
DE:PV3B
EyePoint Pharmaceuticals financials statements
€0.28
At close:-0.01 (-2.80%)
EyePoint Pharmaceuticals (PV3B) Ratios
1 Followers
EyePoint Pharmaceuticals Ratios
DE:PV3B's free cash flow for Q3 2026 was $-88.02M. For the 2026 fiscal year, DE:PV3B's free cash flow was decreased by $-1.21M and operating cash flow was $-86.82M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.88 | 7.81 | 5.45 | 5.00 | 10.05 |
| Quick Ratio | 8.83 | 7.77 | 5.39 | 4.92 | 9.90 |
| Cash Ratio | 2.75 | 2.03 | 4.45 | 2.77 | 7.55 |
| Solvency Ratio | -3.97 | -1.58 | -0.79 | -1.19 | -0.70 |
| Operating Cash Flow Ratio | -6.49 | -2.57 | 0.03 | -1.88 | -2.12 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -6.21 | 0.00 |
| Net Current Asset Value | $ 270.77M | $ 301.34M | $ 255.94M | $ 88.82M | $ 158.75M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.05 | 0.01 | 0.26 | 0.15 |
| Debt-to-Equity Ratio | 0.07 | 0.06 | 0.02 | 0.48 | 0.21 |
| Debt-to-Capital Ratio | 0.07 | 0.06 | 0.02 | 0.32 | 0.18 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.23 | 0.17 |
| Financial Leverage Ratio | 1.19 | 1.24 | 1.33 | 1.87 | 1.43 |
| Debt Service Coverage Ratio | 0.00 | -9236.86 | -55.40 | -7.07 | -9.12 |
| Interest Coverage Ratio | 0.00 | -10418.14 | -60.20 | -31.24 | -10.05 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.30 | 0.10 |
| Interest Debt Per Share | 0.31 | 0.39 | 0.16 | 1.33 | 1.55 |
| Net Debt to EBITDA | 0.34 | 0.60 | 4.01 | 0.51 | 2.78 |
| Profitability Margins | |||||
| Gross Profit Margin | 93.41% | 91.42% | 89.93% | 79.89% | 77.86% |
| EBIT Margin | -738.42% | -302.19% | -150.95% | -239.26% | -143.26% |
| EBITDA Margin | -731.06% | -298.63% | -149.94% | -233.36% | -135.76% |
| Operating Profit Margin | -775.98% | -337.06% | -163.13% | -240.65% | -149.64% |
| Pretax Profit Margin | -738.53% | -302.22% | -153.66% | -246.97% | -158.14% |
| Net Profit Margin | -739.42% | -302.43% | -153.84% | -246.97% | -158.14% |
| Continuous Operations Profit Margin | -739.42% | -302.43% | -153.84% | -246.97% | -158.14% |
| Net Income Per EBT | 100.12% | 100.07% | 100.12% | 100.00% | 100.00% |
| EBT Per EBIT | 95.17% | 89.67% | 94.20% | 102.63% | 105.68% |
| Return on Assets (ROA) | -63.73% | -31.27% | -19.93% | -56.70% | -22.18% |
| Return on Equity (ROE) | -75.78% | -38.89% | -26.58% | -106.11% | -31.68% |
| Return on Capital Employed (ROCE) | -74.45% | -39.48% | -25.71% | -68.33% | -23.06% |
| Return on Invested Capital (ROIC) | -73.99% | -39.48% | -25.71% | -63.51% | -22.98% |
| Return on Tangible Assets | -63.73% | -31.27% | -19.93% | -56.70% | -24.28% |
| Earnings Yield | -17.33% | -31.20% | -8.08% | -78.29% | -16.60% |
| Efficiency Ratios | |||||
| Receivables Turnover | 48.19 | 71.29 | 57.17 | 2.67 | 2.01 |
| Payables Turnover | 0.20 | 0.32 | 0.71 | 1.41 | 1.11 |
| Inventory Turnover | 1.14 | 1.61 | 1.19 | 2.88 | 2.26 |
| Fixed Asset Turnover | 1.55 | 1.48 | 4.50 | 5.60 | 13.54 |
| Asset Turnover | 0.09 | 0.10 | 0.13 | 0.23 | 0.14 |
| Working Capital Turnover Ratio | 0.10 | 0.14 | 0.22 | 0.24 | 0.28 |
| Cash Conversion Cycle | -1525.39 | -920.75 | -198.34 | 3.71 | 13.12 |
| Days of Sales Outstanding | 7.57 | 5.12 | 6.39 | 136.67 | 181.36 |
| Days of Inventory Outstanding | 320.30 | 226.65 | 307.79 | 126.52 | 161.41 |
| Days of Payables Outstanding | 1853.27 | 1152.52 | 512.51 | 259.48 | 329.65 |
| Operating Cycle | 327.88 | 231.77 | 314.18 | 263.19 | 342.77 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.28 | -2.24 | 0.05 | -1.74 | -1.74 |
| Free Cash Flow Per Share | -3.32 | -2.31 | -0.04 | -1.80 | -1.75 |
| Dividend Paid and CapEx Coverage Ratio | -73.20 | -31.15 | 0.54 | -30.23 | -321.13 |
| Capital Expenditure Coverage Ratio | -73.20 | -31.15 | 0.54 | -30.23 | -321.13 |
| Operating Cash Flow Coverage Ratio | -10.53 | -5.77 | 0.38 | -1.40 | -1.28 |
| Operating Cash Flow to Sales Ratio | -7.65 | -2.92 | 0.04 | -1.57 | -1.36 |
| Free Cash Flow Yield | -18.19% | -31.06% | -0.18% | -51.42% | -14.28% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.76 | -3.21 | -12.38 | -1.28 | -6.03 |
| Price-to-Sales (P/S) Ratio | 42.66 | 9.69 | 19.04 | 3.15 | 9.53 |
| Price-to-Book (P/B) Ratio | 4.37 | 1.25 | 3.29 | 1.36 | 1.91 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.50 | -3.22 | -544.85 | -1.94 | -7.00 |
| Price-to-Operating Cash Flow Ratio | -5.57 | -3.32 | 467.26 | -2.01 | -7.03 |
| Price-to-Earnings Growth (PEG) Ratio | -0.16 | -0.12 | 0.37 | -0.04 | 0.14 |
| Enterprise Value Multiple | -5.49 | -2.64 | -8.69 | -0.84 | -4.24 |
| Enterprise Value | 1.26B | 341.57M | 599.76M | 81.32M | 212.61M |
| EV to EBITDA | -5.49 | -2.64 | -8.69 | -0.84 | -4.24 |
| EV to Sales | 40.14 | 7.89 | 13.03 | 1.96 | 5.76 |
| EV to Free Cash Flow | -5.17 | -2.62 | -372.99 | -1.21 | -4.23 |
| EV to Operating Cash Flow | -5.24 | -2.71 | 319.87 | -1.25 | -4.24 |
| Tangible Book Value Per Share | 4.18 | 5.98 | 6.85 | 2.58 | 5.62 |
| Shareholders’ Equity Per Share | 4.18 | 5.98 | 6.85 | 2.58 | 6.41 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.43 | 0.77 | 1.18 | 1.11 | 1.28 |
| Net Income Per Share | -3.17 | -2.32 | -1.82 | -2.74 | -2.03 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.02 | 1.03 | 1.10 |
| Research & Development to Revenue | 7.05 | 3.07 | 1.41 | 1.20 | 0.77 |
| SG&A to Revenue | 1.65 | 1.21 | 0.87 | 0.84 | 0.69 |
| Stock-Based Compensation to Revenue | 0.89 | 0.85 | 0.26 | 0.34 | 0.20 |
| Income Quality | 1.04 | 0.96 | -0.03 | 0.64 | 0.86 |
Currency in USD

